Evidence map›Paper›PMID 40530723›Full record

ArticleCurrent topics in medicinal chemistry2025

Benzoxathiolone-Thiazolidinone Hybrids: A New Class in the Search for Anticancer Agents.

Eliza de Lucas Chazin, Ligia Souza da Silveira Pinto, Victor Facchinetti, Paula de Aquino Soeiro Portilho, Breno de Souza Bernardes, Claudia Regina Brandao Gomes, Emerson Lucena da Silva, Luina Benevides Lima, Felipe Pantoja Mesquita, Pedro Filho Noronha de Souza and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Current topics in medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Eliza de Lucas ChazinDepartment of Organic Chemistry, Federal Fluminense University, Niterói-RJ, Brazil.
Ligia Souza da Silveira PintoDepartment of Organic Chemistry, Federal Fluminense University, Niterói-RJ, Brazil.
Victor FacchinettiInstitute of Drug Technology, Oswaldo Cruz Foundation, Rio de Janeiro-RJ, Brazil.
Paula de Aquino Soeiro PortilhoDepartment of Organic Chemistry, Federal Fluminense University, Niterói-RJ, Brazil.
Breno de Souza BernardesDepartment of Organic Chemistry, Federal Fluminense University, Niterói-RJ, Brazil.
Claudia Regina Brandao GomesInstitute of Drug Technology, Oswaldo Cruz Foundation, Rio de Janeiro-RJ, Brazil.
Emerson Lucena da SilvaDepartment of Physiology and Pharmacology, Federal University of Ceará, Fortaleza-CE, Brazil.
Luina Benevides LimaDepartment of Physiology and Pharmacology, Federal University of Ceará, Fortaleza-CE, Brazil.
Felipe Pantoja MesquitaDepartment of Physiology and Pharmacology, Federal University of Ceará, Fortaleza-CE, Brazil.
Pedro Filho Noronha de SouzaDepartment of Physiology and Pharmacology, Federal University of Ceará, Fortaleza-CE, Brazil.
Raquel Carvalho MontenegroDepartment of Physiology and Pharmacology, Federal University of Ceará, Fortaleza-CE, Brazil.
Marcus Vinicius Nora De SouzaInstitute of Drug Technology, Oswaldo Cruz Foundation, Rio de Janeiro-RJ, Brazil.ORCID 0000-0003-1566-8110
Thatyana Rocha Alves VasconcelosDepartment of Organic Chemistry, Federal Fluminense University, Niterói-RJ, Brazil.ORCID 0000-0002-3421-191X

Funding

CNPq, Conselho Nacional de Desenvolvimento Científico e Tecnológico 310474/2015-9Faperj, Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro E-26/010.001574/2019
6 · The paper itself

Abstract

backgroundCancer continues to be a significant public health issue and one of the leading causes of death globally. In this context, developing new, potent, and more specific treatments against this disease is urgent.

methodsA total of 15 benzoxathiolone-thiazolidinones hybrids were synthesized in a 5-step route and tested for their cytotoxicity against five human cancer cell lines: AGP-01 (gastric), SKMEL- 103 (melanoma), HCT-116 (colon), CAL27 (tongue), and K562 (leukemia), as well as a nontumoral cell line MRC-5.

resultsCompounds 3-(6-hydroxy-2-oxobenzo[d][1,3]oxathiol-5-yl)-2-(4-nitrophenyl)thiazolidin- 4-one and 2-(2,4-dichlorophenyl)-3-(6-hydroxy-2-oxobenzo[d][1,3]oxathiol-5-yl)thiazolidin-4-one exhibited good activity against the K562 leukemia cell line, with IC

conclusionThe study suggests these benzoxathiolone-thiazolidinone hybrids could be promising lead compounds for developing new anticancer agents targeting leukemia.

Indexed as

Antineoplastic AgentsThiazolidinesCell Line, TumorCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansMolecular Docking SimulationMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsThiazolidinesBenzoxathioloneCancerDockingLeukemiaSynthesisThiazolidinone

Identifiers

PMID40530723

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.